Provides that purchase of insulin is not subject to deductible and requires health insurers to limit copayments and coinsurance for insulin.
Impact
This bill will have a significant impact on state laws regarding health insurance coverage, specifically those regulating health benefits plans for individuals and small employers. By mandating that plans provide insulin coverage free from deductibles and imposing limits on copayments, the bill aims to reduce unnecessary healthcare expenditure and ensure better access to diabetes management resources. Additionally, it emphasizes the need for transparency in pricing from drug manufacturers, addressing long-standing concerns about the lack of competition and accountability in the insulin market, which have contributed to skyrocketing prices over time.
Summary
Senate Bill S301 addresses the escalating costs of insulin by mandating health insurers in New Jersey to provide coverage for insulin purchases without subjecting them to deductibles. It also limits the maximum copayment or coinsurance for insulin to $50 per 30-day supply, thereby directly alleviating the financial burden on diabetes patients who rely on this essential medication. The legislation's primary aim is to ensure that individuals with diabetes have access to necessary treatments without facing exorbitant out-of-pocket costs that can jeopardize their health and financial stability.
Contention
While S301 is primarily framed as a consumer protection measure, there are potential points of contention. Some stakeholders may argue that the bill could lead to increased insurance premiums as insurers adapt to these mandated coverage requirements. Additionally, concerns may arise over the bill's implications for the broader pharmaceutical market, particularly regarding how it interacts with existing incentive structures for generic insulin production and pricing practices among manufacturers. Critics may also point out that while limiting costs is beneficial, there are systemic issues within healthcare financing that require more extensive reforms to yield sustainable benefits.
Same As
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.